Hepatocellular Carcinoma (HCC) Clinical Trial
Official title:
A Phase II Study Evaluating Reduced Starting Dose and Dose Escalation of Cabozantinib as Second-line Therapy for Advanced HCC in Patients With Preserved Liver Function
Verified date | December 2023 |
Source | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Open-label, single arm, multicenter phase II trial assessing the tolerability of a reduced starting dose of 40 mg cabozantinib for 4 weeks and subsequent dose escalation to 60 mg cabozantinib until disease progression or intolerable toxicities.
Status | Active, not recruiting |
Enrollment | 40 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Fully-informed written consent. - Males and females = 18 years of age. *There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the study gender-independently. - Patients with HCC who have been previously treated with any first line therapy. - Locally advanced or metastatic and/or unresectable HCC with preserved liver function (Child-Pugh A only, if liver cirrhosis is present) with diagnosis confirmed by histology/cytology or clinically by guideline criteria. - Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies. - ECOG performance status = 2. - Resolution of any acute, clinically significant treatment-related toxicity from prior therapy to Grade 1 prior to study entry, with the exception of alopecia. - Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment. - For women of childbearing potential (WOCBP): agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods from the time of signing the informed consent through at least 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse. Male patients, even if surgically sterilized (i.e. status post-vasectomy) must agree to practice effective barrier contraception (e.g. condom) and to refrain from sperm donation during the entire study treatment period and through at least 4 months after the last dose of study drug or agree to completely abstain from heterosexual intercourse. Exclusion Criteria: - Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 4 months. - Significant portal hypertension (moderate or severe ascites). Significant hypertension, defined as blood pressure = 140 mmHg (systolic) or = 90 mmHg (diastolic) in repeated measurements. - Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC. - Patients with impaired liver function defined as Child-Pugh B or C, if liver cirrhosis is present. - Severely impaired kidney function (defined as creatinine > 2 mg/dl and/or creatinine clearance < 45 mL/min). - Elevations of AST/ALT > 5 x ULN at baseline. - Presence of encephalopathy in past 12 months. - Significant cardiovascular disease (such as NYHA Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina. - Baseline QTcF > 500 ms. - Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study. - Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia. - Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications. - Treatment with investigational systemic therapy within 28 days or five times the elimination half-life of the investigational product, whichever is longer, prior to initiation of study treatment. - Prior cabozantinib use. - Known or suspected hypersensitivity to cabozantinib or any other excipients of the IMP. - Rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. - Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. - Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG. - Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG]. |
Country | Name | City | State |
---|---|---|---|
Germany | HELIOS Klinikum Bad Saarow | Bad Saarow | |
Germany | BAG / Onkologische Gemeinschaftspraxis | Dresden | |
Germany | Ev. Kliniken Essen-Mitte, Klinik für Internistische Onkologie | Essen | |
Germany | Universitätsklinikum Essen | Essen | |
Germany | Institute for Clinical Cancer Research Krankenhaus Nordwest | Frankfurt | |
Germany | Klinikum der Johann-Wolfgang-Goethe Universität | Frankfurt | |
Germany | Universitätsklinikum Gießen und Marburg | Gießen | |
Germany | Universitätsklinikum Köln AöR | Köln | |
Germany | Universität Leipzig KöR, Medizinische Fakultät Department für Innere Medizin, Neurologie Klinik für Gastroenterologie | Leipzig | |
Germany | Klinikum rechts der Isar Technische Universität München Klinik und Poliklinik für Innere Medizin II | Müchen |
Lead Sponsor | Collaborator |
---|---|
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Johann Wolfgang Goethe University Hospital, Prof. Dr. med. Trojan |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Treatment discontinuation rate due to treatment-related adverse events | Any unresolved intolerable Grade 2 TRAE or unresolved Grade = 3 TRAE after 60 mg or 40 mg or any intolerable Grade 2 TRAE or Grade = 3 TRAE after 20 mg will count as treatment discontinuation due to AE. | 27 months | |
Secondary | Overall survival | Time from the date of enrollment to the date of death from any cause. Subjects who have not died by the date of data cutoff will be right censored at the last known date alive. | 27 months | |
Secondary | Progression free survival (PFS) according to RECIST 1.1 | Time from the date of enrollment to the date of first observed disease progression (investigator assessment according to RECIST 1.1) or death from any cause. Subjects who have died without a reported disease progression will be considered to have progressed on the date of their death. Subjects who did not progress or have died will be right censored on the date of their last evaluable tumor assessment. | at 10 weeks | |
Secondary | Objective response rate (ORR) according to RECIST 1.1 | Objective response rate will be assessed according to RECIST 1.1 (refer to Appendix 5). Objective response rate will be defined as the proportion of subjects experiencing a confirmed complete response (CR) or confirmed partial response (PR) per RECIST 1.1. | 27 months | |
Secondary | Time on treatment | Time on treatment defined as the interval from therapy initiation until premature discontinuation. | 27 months | |
Secondary | Treatment exposure | Treatment exposure defined as summary of specific dose intensities on treatment (including dose reductions and interruptions). | 27 months | |
Secondary | Treatment-related and -unrelated toxicities (AEs, SAEs) according to NCI CTCAE v5.0 | All observed treatment-related and -unrelated toxicities (type, incidence and severity of AEs and SAEs) and side effects will be graded according to NCI CTCAE v5.0 and the degree of association of each with the study treatment assessed and summarized. The treatment related serious adverse events rate (SAE) will be determined. | 27 months | |
Secondary | Quality of Life with the EORTC QLQ-C30 patient questionnaire | Patient reported outcome assessed by the validated EORTC patient quality of life questionnaire QLQ-C30. The questionnaire evaluates the patient's health and activities in everyday life. Values reach from 1 (not at all) to 4 (very much). Low values mean a better outcome. | 27 months | |
Secondary | Correlation of biomarkers potentially associated with clinical efficacy (OS, PFS and ORR) | The TR projects might include the assessment of the following:
FFPE tissue for IHC staining; FFPE tissue for nucleic isolation to assess the expression of biomarkers, determination of genetic alterations in HCC (panel sequencing) or to determine the mutational load. |
27 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03007212 -
Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis
|
Phase 4 | |
Terminated |
NCT03236649 -
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
|
Phase 3 | |
Withdrawn |
NCT04044326 -
The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors
|
N/A | |
Recruiting |
NCT04687969 -
Multimodal Machine Learning Characterization of Solid Tumors
|
||
Completed |
NCT02562755 -
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
|
Phase 3 | |
Withdrawn |
NCT02406508 -
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
|
Phase 2 | |
Completed |
NCT01972672 -
The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT01247298 -
A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma
|
Phase 0 | |
Completed |
NCT03735628 -
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02188901 -
Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study
|
N/A | |
Terminated |
NCT01433016 -
Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI
|
Phase 2 | |
Withdrawn |
NCT04465734 -
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
|
Phase 3 | |
Recruiting |
NCT05057013 -
HMBD-001 in Advanced HER3 Positive Solid Tumours
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03753659 -
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
Terminated |
NCT03144661 -
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
|
Phase 1 | |
Not yet recruiting |
NCT01821482 -
A Study of DC-CIK to Treat Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT03516071 -
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
|
Phase 2 | |
Completed |
NCT01761266 -
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
|
Phase 3 | |
Not yet recruiting |
NCT06345001 -
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer
|
Phase 1 | |
Completed |
NCT02794805 -
Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis
|
Phase 2 |